Literature DB >> 14742594

Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey.

S Sevim1, O Dogu, H Kaleagasi, M Aral, O Metin, H Camdeviren.   

Abstract

BACKGROUND AND OBJECTIVES: Restless legs syndrome (RLS) is an important and common cause of insomnia, and previous studies indicate that psychiatric wellbeing may be impaired among RLS patients. We aimed to investigate the interaction between anxiety/depression and RLS in a population based survey.
METHODS: Data were drawn from the Mersin University Neuro-Epidemiology Project, a representative community sample of adults aged over 17 years residing in Mersin (n = 3234). Subjects found to be positive for RLS (n = 103) were evaluated for symptoms of anxiety and depression using the Hamilton Anxiety and Depression Scales and compared with the same number of contemporaneous control subjects.
RESULTS: Significantly greater anxiety and depression symptoms were observed among patients with RLS than in the control subjects. Our data also seem to provide initial evidence of a correlation between the severity of RLS and of anxiety and depression symptoms (r = 0.21, p = 0.03 and r = 0.201, p = 0.04 respectively).
CONCLUSIONS: Assessment of psychiatric status of RLS patients can be helpful and sometimes necessary to determine additional features and treatment strategies of this bothering condition. Further studies are needed to replicate our findings using longitudinal data.

Entities:  

Mesh:

Year:  2004        PMID: 14742594      PMCID: PMC1738920     

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  24 in total

1.  Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.

Authors:  N Turjanski; A J Lees; D J Brooks
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

2.  Restless legs syndrome: a disease in search of identity.

Authors:  S Chokroverty; J Jankovic
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

3.  SYMPTOM OF RESTLESS LEGS.

Authors:  C A GORMAN; P J DYCK; J S PEARSON
Journal:  Arch Intern Med       Date:  1965-02

4.  Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome.

Authors:  C Trenkwalder; W A Hening; A S Walters; S S Campbell; K Rahman; S Chokroverty
Journal:  Mov Disord       Date:  1999-01       Impact factor: 10.338

5.  Fluoxetine and restless legs syndrome.

Authors:  R Bakshi
Journal:  J Neurol Sci       Date:  1996-10       Impact factor: 3.181

6.  Restless leg syndrome exacerbated by sertraline.

Authors:  R Hargrave; D J Beckley
Journal:  Psychosomatics       Date:  1998 Mar-Apr       Impact factor: 2.386

7.  Mianserin and restless legs.

Authors:  J Markkula; H Lauerma
Journal:  Int Clin Psychopharmacol       Date:  1997-01       Impact factor: 1.659

8.  Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers.

Authors:  R J Salín-Pascual; L Galicia-Polo; R Drucker-Colín
Journal:  J Clin Psychiatry       Date:  1997-08       Impact factor: 4.384

9.  Restless legs syndrome and paroxetine.

Authors:  F J Sanz-Fuentenebro; A Huidobro; A Tejadas-Rivas
Journal:  Acta Psychiatr Scand       Date:  1996-12       Impact factor: 6.392

10.  Panic disorder and cigarette smoking behavior.

Authors:  M Amering; B Bankier; P Berger; H Griengl; J Windhaber; H Katschnig
Journal:  Compr Psychiatry       Date:  1999 Jan-Feb       Impact factor: 3.735

View more
  40 in total

1.  Restless legs syndrome: relationship between prevalence and latitude.

Authors:  Brian B Koo
Journal:  Sleep Breath       Date:  2011-12-31       Impact factor: 2.816

2.  Restless legs syndrome and hypertension in Chinese pregnant women.

Authors:  Shengli Ma; Xiaoping Shang; Yu Guo; Gangqiong Liu; Jinjian Yang; Rui Xue
Journal:  Neurol Sci       Date:  2015-02-03       Impact factor: 3.307

3.  Affective personality as cognitive-emotional presymptom profiles regulatory for self-reported health predispositions.

Authors:  T Archer; B Adolfsson; E Karlsson
Journal:  Neurotox Res       Date:  2008-08       Impact factor: 3.911

4.  Restless legs syndrome in an appalachian primary care population: prevalence, demographic and lifestyle correlates, and burden.

Authors:  Kim E Innes; Kathryn L Flack; Terry Kit Selfe; Sahiti Kandati; Parul Agarwal
Journal:  J Clin Sleep Med       Date:  2013-10-15       Impact factor: 4.062

5.  Restless legs syndrome, sleep, and quality of life among adolescents and young adults.

Authors:  Graciela E Silva; James L Goodwin; Kimberly D Vana; Monica M Vasquez; Peter G Wilcox; Stuart F Quan
Journal:  J Clin Sleep Med       Date:  2014-07-15       Impact factor: 4.062

6.  Prospective study of restless legs syndrome and risk of depression in women.

Authors:  Yanping Li; Fariba Mirzaei; Eilis J O'Reilly; John Winkelman; Atul Malhotra; Olivia Ifeoma Okereke; Alberto Ascherio; Xiang Gao
Journal:  Am J Epidemiol       Date:  2012-07-17       Impact factor: 4.897

Review 7.  Restless legs syndrome and pregnancy: a review.

Authors:  Prachaya Srivanitchapoom; Sanjay Pandey; Mark Hallett
Journal:  Parkinsonism Relat Disord       Date:  2014-04-08       Impact factor: 4.891

8.  The effects of a MAP2K5 microRNA target site SNP on risk for anxiety and depressive disorders.

Authors:  Kevin P Jensen; Henry R Kranzler; Murray B Stein; Joel Gelernter
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2014-01-16       Impact factor: 3.568

9.  Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management.

Authors:  Magdolna Hornyak
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

10.  No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome.

Authors:  Erika Driver-Dunckley; Donald Connor; Joe Hentz; Marwan Sabbagh; Nina Silverberg; Jose Hernandez; Linda Vedders; Virgilio Gerald Evidente; Holly Shill; John Caviness; Charles Adler
Journal:  Mov Disord       Date:  2009-09-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.